Ασφάλεια και αποτελεσματικότητα του BEVACIZUMAB ως θεραπεία συντήρησης σε ασθενείς με καρκίνο πνεύμονα

Postgraduate Thesis uoadl:1310294 271 Read counter

Unit:
Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences
Deposit date:
2012-11-15
Year:
2012
Author:
Σταματοπούλου Σοφία
Supervisors info:
Κων/νος Ν. Συρίγος (Επιβλέπων) , Aριστείδης Πολύζος, Ιωάννης Μούντζιος
Original Title:
Ασφάλεια και αποτελεσματικότητα του BEVACIZUMAB ως θεραπεία συντήρησης σε ασθενείς με καρκίνο πνεύμονα
Languages:
Greek
Summary:
Purpose: The objective of this study is to evaluate the effectiveness and
safety of the maintenance treatment with humanized monoclonal antibody
Bevacizumab, in lung cancer patients.
Materials and Methods: The present study was done in two phases. At first, we
studied some of the most important scientific publications concerning
maintenance therapy and the role of angiogenesis in lung cancer, as well as the
introduction of new biological agents in targeted cancer therapy. At the second
part of this study, we report the results concerning patients’ response to
maintenance therapy with Bevacizumab, until they develop serious side effects
or relapse. Response to treatment was evaluated at a group of twenty patients
who had received first-line chemotherapy with Bevacizumab.
Results: From the lung cancer patients examined, 75% of those with stageIV and
20% of those with stage IIIB, showed response to Bevacizumab treatment, and a
good toxicity profile. Regarding patients with tumor stage IIIA, one of them
exhibited partial response to treatment (50%) and the other one showed stable
disease (50%). Additionally, 66.7% of the patients with tumor stage IIIB and
46.7% of those with tumor stage IV, showed partial response to treatment, while
33.3% and 53.3% of those with tumor stage IIIB and stage IV, respectively,
exhibited stable disease. Mean progression-free survival was 8.6 months and
median overall survival, was 13.9 months.Treatment-related toxicity, grade 3 to
4, was observed in 5% of the patients.
However, the number of patients included in this study is very small, and thus
is very difficult to draw a safe conclusion.
Conclusion: The identification and utilization of novel tumor markers as well
as the analysis of the tumor molecular profile can contribute in the
personalized approach which is required for optimal management of lung cancer
patients.
Keywords:
Humanized monoclonal antibody , Angeiogenesis, Lung Neoplasms, Maintenance treatment
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
65
Number of pages:
79
File:
File access is restricted only to the intranet of UoA.

document.pdf
1 MB
File access is restricted only to the intranet of UoA.